Complement Targets Newborn Retinal Ganglion Cells for Phagocytic Elimination by Microglia

Sarah R. Anderson  
*University of Utah*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/neurobiology_pp

Part of the Developmental Neuroscience Commons, Embryonic Structures Commons, and the Nervous System Commons

Repository Citation


This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Neurobiology Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Development/Plasticity/Repair

Complement Targets Newborn Retinal Ganglion Cells for Phagocytic Elimination by Microglia

Sarah R. Anderson,1,2 Jianmin Zhang,1 Michael R. Steele,1 Cesar O. Romero,1 Amanda G. Kautzman,3 Dorothy P. Schafer,1 and Monica L. Vetter1

1Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, Utah 84112, 2Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, Utah 84112, and 3Department of Neurobiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655

Microglia play important roles in shaping the developing CNS, and at early stages they have been proposed to regulate progenitor proliferation, differentiation, and neuronal survival. However, these studies reveal contradictory outcomes, highlighting the complexity of these cell–cell interactions. Here, we investigate microglia function during embryonic mouse retina development, where only microglia, progenitors, and neurons are present. In both sexes, we determine that microglia primarily interact with retinal neurons and find that depletion of microglia via conditional KO of the Csf1 receptor results in increased density of retinal ganglion cells (RGCs). Pharmacological inhibition of microglia also results in an increase in RGCs, with no effect on retinal progenitor proliferation, RGC genesis, or apoptosis. We show that microglia in the embryonic retina are enriched for phagocytic markers and observe engulfment of nonapoptotic Brn3-labeled RGCs. We investigate the molecular pathways that can mediate cell engulfment by microglia and find selective downregulation of complement pathway components with microglia inhibition, and further show that C1q protein marks a subset of RGCs in the embryonic retina. KO of complement receptor 3 (CR3; Itgam), which is only expressed by microglia, results in increased RGC density, similar to what we observed after depletion or inhibition of microglia. Thus, our data suggest that microglia regulate neuron elimination in the embryonic mouse retina by complement-mediated phagocytosis of non-apoptotic newborn RGCs.

Key words: complement; microglia; phagocytosis; retina; retinal ganglion cell

Significance Statement

Microglia are emerging as active and important participants in regulating neuron number in development, during adult neurogenesis, and following stem cell therapies. However, their role in these contexts and the mechanisms involved are not fully defined. Using a well-characterized in vivo system, we provide evidence that microglia regulate neuronal elimination by complement-mediated engulfment of nonapoptotic neurons. This work provides a significant advancement of the field by defining in vivo molecular mechanisms for microglia-mediated cell elimination. Our data add to a growing body of evidence that microglia are essential for proper nervous system development. In addition, we elucidate microglia function in the developing retina, which may shed light on microglia involvement in the context of retinal injury and disease.

Introduction

Microglia, the resident innate immune cells of the CNS, shape the developing brain: from regulating the survival of neurons to refining circuits (Nayak et al., 2014; Li and Barres, 2018). Microglia derive from erythromyeloid precursors in the yolk sac and migrate to the brain and retina at early embryonic stages (Ginhoux et al., 2013). Microglia impact the generation and survival of neurons in vitro, during development, and in adult neurogenic zones (Ekdahl et al., 2009; Sato, 2015). However, microglia can have varying effects on proliferation, differentiation, and neuronal survival; and consequently, the mechanisms by which microglia regulate neurogenesis in vivo are not fully understood.

Microglia maintain homeostasis by clearing dead or dying cells as well as directly regulating death via secretion of cytokines or reactive oxygen species (Bilimoria and Stevens, 2015). Furthermore, growing evidence suggests that microglia can execute stressed but viable cells by phagocytosis, a process called phagocytosis (Brown and Neher, 2014; Vilalta and Brown, 2018). While...
phagoptosis has primarily been characterized in vitro, there is evidence that microglia engulf viable neural progenitors in the developing cortex (Cunningham et al., 2013) and nonapoptotic neurons in contexts of injury or disease (Neher et al., 2013; Zhao et al., 2015; Luo et al., 2016; Alawieh et al., 2018). Whether microglia regulate neuronal survival by phagoptosis in the developing CNS is unknown.

Multiple cell surface cues, or “eat-me signals,” stimulate microglial phagocytosis (Ravichandran, 2010; Fourgeaud et al., 2016). The complement cascade is a highly conserved signaling pathway important for innate immunity; allowing immune cells to attack membranes or phagocytose invaders (Ricklin et al., 2010). In the CNS, C1q, an initiation component of the complement pathway, tags neuronal synapses for microglial phagocytosis both in development and disease, including pruning of retinal ganglion cell (RGC) synapses for activity-dependent refinement during postnatal periods (Stevens et al., 2007; Schafer et al., 2012; Stephan et al., 2012; Hong et al., 2016). At present, the molecular signals driving phagoptosis in vivo are largely undetermined, and complement has not been implicated in the phagocytosis of entire neurons in development.

In the retina, complex intrinsic and extrinsic processes regulate the production of seven major groups of retinal cells (Bassett and Wallace, 2012). Like other CNS regions, a substantial number of retinal neurons will be eliminated, a process presumed to be driven by apoptosis (Francisco-Morcillo et al., 2014). RGCs are the earliest-born retinal neurons and undergo the largest reduction in density (Perry et al., 1983; Farah, 2006), which is important for retinal function (Pequignot et al., 2003; Chen et al., 2013). Shortly after birth, a large wave of RGC apoptotic death occurs (Pequignot et al., 2003), but a less-studied, embryonic wave of RGC loss has been observed in monkey, cat, chick, rat, and mouse (Pequignot et al., 2003; Farah, 2006). However, it is currently unclear what is driving this embryonic wave of RGC loss because there is minimal apoptosis in the mouse RGC layer at this time.

The embryonic retina allows for unambiguous assessment of microglial influence on neurogenesis and/or neuronal survival because only microglia, retinal progenitors, and newborn neurons are present. Here, we find that microglia preferentially reside adjacent and interact with neurons. By genetic depletion and pharmacological inhibition of microglia, we demonstrate that microglia normally limit RGC density and provide evidence that this is via phagocytic elimination of nonapoptotic newborn cells. We find that complement proteins are highly expressed in the developing retina and are selectively regulated by inhibition of microglia. Finally, loss of complement receptor 3 (CR3), which is only expressed on microglia, results in increased RGC number. This is via phagocytic elimination of nonapoptotic newborn cells. We find that complement proteins are highly expressed in the developing retina and are selectively regulated by inhibition of microglia. Finally, loss of complement receptor 3 (CR3), which is only expressed on microglia, results in increased RGC number. Consequently, we provide evidence for a previously unknown mechanism of RGC elimination and suggest a new role for complement in the phagocytosis of entire, nonapoptotic neurons.

Materials and Methods

Animals and procedures. All animals were treated within the guidelines of the University of Utah Institutional Animal Care and Use Committee, and all experiments were Institutional Animal Care and Use Committee-approved. C57B6/2J and B6.Csf1r−/− (021212) mice were purchased from The Jackson Laboratory. The B6.Cx3cr1gfp+/− mice (Jung et al., 2000) were a gift from Richard Lang with permission from Steffen Jung. B6.Cx3cr1creERT2 mice (Yona et al., 2013) were a gift from Steffen Jung. B6.Rosa26Tdtomato mice (Madsen et al., 2010) were a gift from Mario Capecchi. Postnatal CR3 KO and littersmate control tissue was a gift from Dorothy Schafer (Coxon et al., 1996). Mice were housed in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility with 12 h light/12 h dark cycles and ad libitum access to food and water. Timed matings were used to determine embryonic stages, and both sexes were used for all experiments. The morning a plug was detected was considered embryonic day 0.5. Minocycline (120 mg/kg) or the same volume of vehicle, 5% succrose in PBS, was administered once a day by oral gavage to pregnant dams from embryonic day (e) 12.5–15.5 or e12.5–e13.5. Tamoxifen was administered to pregnant dams by oral gavage on e11.5 and e13.5 at 2, 3, and 3 mg, respectively; 45 μg/ml BW of 10 μg/ml stock BrdU was injected intraperitoneally 24 h before death; 4 μl/g BW of 5 mM stock 5-ethynyl-2-deoxyuridine (EdU) was injected intraperitoneally 48 h before death. Animals of either sex used for experiments were euthanized by isoflurane asphyxiation followed by cervical dislocation.

Tissue processing. Following death, retinas were disected in ice-cold 0.1 M PBS. Whole heads were fixed in 4% PFA for 45 min to an hour. Heads were washed 3 times for 15 min in PBS and underwent 12–16 h consecutive treatments with 15% and 30% sucrose in PBS at 4°C. Heads were then embedded in OCT compound (Tissue-Tek), stored at −80°C, and sectioned at 16 μm thickness. For retinal whole mounts, eyes were removed from the head and retinas were carefully dissected from the rest of the eye (cornea, lens, retinal pigment epithelium, hyaloid vasculature, vitreous, ciliary body) in ice-cold PBS. Whole neural retinas were washed in PBS for 10–20 min and then fixed in 4% PFA for 15–30 min at room temperature with rocking.

Immunohistochemistry. Frozen sections were placed in ice-cold PBS for 10 min, blocked for 1 h at room temperature (0.2% Triton-X, 10% BSA, 10% normal donkey serum in 0.01 M PBS), then incubated in primary antibody overnight at 4°C (0.5% Triton-X, 5% BSA in 0.01 M PBS). The following day, sections were washed 3× with PBS and incubated in secondary antibodies (5% BSA in PBS) for 2 h at room temperature, washed, and mounted with Vectashield mounting medium with DAPI (H-1200, Vector Laboratories). For whole-mount immunostaining, retinas were incubated in primary antibody at 4°C for 3 d. An extra incubation in 4 M HCl for 2 h and wash with a sodium borate buffer was used for BrdU detection before primary antibody incubation. EdU was detected per the Click-iT Plus Kit instructions (C10640, Thermo Fisher Scientific). Primary antibodies used are as follows: goat Brn3 (1:150; Santa Cruz Biotechnology sc-6026), rabbit phospho-histone H3 (PH3) (1:500, Millipore 66-570), rabbit cleaved caspase-3 (CC3, 1:500, BD Biosciences 559565), mouse Rsr1 (1:250, Santa Cruz Biotechnology sc-365252), mouse Brn3a (1:50, EMD Millipore MAB1585), rabbit calbindin (1:2000, EMD Millipore PC253L), goat GFP (1:2000, Abcam ab5450), rabbit Iba1 (1:1000, Wako 019-19741), mouse BrdU (1:500, Thermo Fisher Scientific B35128), mouse Cd68 (1:300, Bio-Rad MCA1957), rabbit Clq (11500, Abcam ab182451), and rat Cd11b (1:50, BD Biosciences 6536890). Secondary antibodies were produced in donkey against goat, mouse, and rabbit IgGs and conjugated to AlexaFluor-488, -555, -647, or -647 (Thermo Fisher Scientific).

Confocal microscopy and image analysis. Confocal images were acquired on an inverted Nikon A1R Confocal Microscope. For retinal cross sections, 36 multipoint images were acquired (on average) at 20× objective with a 3× digital zoom to obtain a 0.2 μm pixel resolution. Multipoints were stitched with a 10% overlap. Stacks through the Z plane at 0.8 μm steps spanning the entire thickness were max projected (−16 μm). Images of retinal whole mounts were on average 144 multipoint images of +30 μm thickness. Image acquisition settings were consistent across ages and genotypes. All analysis was performed manually and blinded using Nikon Elements software. For microglia distribution, every fourth section throughout the retina was analyzed. For all RGC counts (Brn3, BrdU, and EdU), the dorsal central regions (300 μm long, −0.04 mm²) of 5 or 6 central sections per animal were analyzed. Only one retina per animal was analyzed unless otherwise specified. RGC density was calculated along 300 μm of central retina for P0-depleted and C3R WT/KO animals. Microglial density for P0 C3R WT and KOs was calculated by Iba1 counts of the central retina (300 μm long, −0.05 mm² area). Microglia density and apoptosis analysis at e13.5 and e16.5 were done on entire cross sections of 5 or 6 central sections per animal. For 3D reconstruction of microglia-RGC interactions, IMARIS software (Bitplane) was used. In brief, high-resolution confocal images (20× objective...
tive, 8 × digital zoom) through Z (0.16 μm steps) were uploaded into IMARIS to create 3D renderings. N > 5 animals were imaged.

Whole-retina qRT-PCR. After death, retinas were carefully dissected in RNase-free conditions using ice-cold RNase-free PBS, removing all non-neural eye tissue (ciliary body, pigmented epithelium, vitreous including hyaloid vasculature at embryonic stages). Promptly, retinas were mechanically dissociated by careful trituration using a sterile 1 ml syringe and 26-gauge needle in RLT buffer. Samples were frozen at −80°C until extraction.

RNA was extracted using an RNeasy Micro Kit (Qiagen, 74004). The concentration and purity of the RNA were measured by a spectrophotometer (NanoDrop ND-1000). First strand cDNA synthesis was performed using the SuperScript III First Strand cDNA synthesis kit (Invitrogen, 11752). Quantitative real-time PCR (qRT-PCR) was performed using SYBR Select Master mix and run on the 7900 HT Fast Real-Time PCR system with QuantStudio 12K Flex software (Applied Biosystems) at the University of Utah Genomics Core. Relative quantification was determined by ΔΔCt, using the QuantStudio Software. Genes of interest were normalized to β-actin. Primers were designed using Primer-BLAST software. Forward and reverse primer sequences in the 5′ to 3′ orientation are as follows: β-actin, TGAGAAGCAGGAATCGTGCTGCTG, TCTGTGCAATGATGATACCTG; Iba1, CGTCTGATGGGA GTTATGATCAG, GACGTGGACGACGCTTGGT; VNR, GTGTCCAACTGCACAGCAAG, GCAGACGTGAATGTCGCAAT; Mertk, GCTGGTCTAGGAGAAGGAG; GGC, AACACACGAGGAGGAGG; Cd11b, GAG; Cd68, GAG; Lrp, GAG; and positioning in the zebrafish CNS (for review, see Casano et al., 2016) during development, and apoptosis facilitates microglia entry into the Nbl directly contacting Brn3+ cells. Therefore, we also assessed the distribution and contact of microglia to cleaved caspase-3-positive (CC3+) cells.

Results
Microglia primarily associate with neurons in the developing retina
Microglia are present as early as embryonic day (e) 11.5 in the mouse retina, shortly after the onset of retinal neurogenesis, shown by immunostaining of activation marker F4/80 (Santos et al., 2008). To obtain a more detailed understanding of microglia distribution during embryonic retinal neurogenesis, we performed Iba1 immunostaining on cryosections from the Cx3cr1-GFP knockin mouse line (Jung et al., 2000). Cx3CR1 (fractalkine receptor), and Iba1, a calcium binding protein, are expressed in microglia and other leukocytes, including circulating monocytes and macrophages (Jung et al., 2000). Retinal microglia were identified as GFP+Iba1+cells within the retinal parenchyma, distinguishable from GFP+Iba1+macrophage populations outside of the retina, including vitreal macrophages (Fig. 1A, yellow arrowheads). We confirmed that these cells within the retina selectively express the microglia-specific marker P2RY12 and not the mono-cyte marker CCR2 (data not shown). At e12.5, e16.5, and postnatal day (P0), Iba1 colocalized with GFP, but Iba1 levels were more variable (Fig. 1A–C). The density of microglia appeared highest at e12.5, consistent with previous work (Santos et al., 2008), and was dynamic throughout development. Using whole-retina qRT-PCR, we found that, relative to adult (P60), Cx3cr1 and Iba1 gene expression was highest at e12.5, decreased during mid-embryonic stages, and increased again at P0, consistent with the densities of microglia observed by immunostaining (Fig. 1D) (n ≥ 3 each). The dramatic expansion of the retina during the embryonic period results in reduced density of microglia, although microglia numbers also continue to increase (data not shown).

The embryonic retina consists of dividing progenitors and other neurons, both of which can be influenced by microglia in other contexts (for review, see Li and Barres, 2018), so we sought to determine with which cell populations microglia may be associating. Before e17.5, the retina can be divided into two main layers: the differentiated cell layer (DCL), consisting of newborn RGCs, amacrine cells, and horizontal cells, and the neuroblastic layer (Nbl) comprised of mainly retinal progenitor cell bodies with cones occupying the future photoreceptor layer along the apical surface (outlined in Fig. 1B’). Other newborn neurons, including RGCs, begin to differentiate at the apical surface of the retina and migrate through the Nbl to the DCL. First, we analyzed microglia density in the two major layers of the retina at e12.5 (n = 4), e14.5 (n = 4), and e16.5 (n = 6). Two-way ANOVA found a significant difference across ages [F2,22 = 33.12, p < 0.0001] and retinal layers [F2,22 = 122.3, p < 0.0001]. At every time point assessed, microglial density was highest in the DCL by Sidak’s multiple-comparisons test (Fig. 1E; e12.5, p < 0.0001; e14.5, p = 0.0122; e16.5, p < 0.0001). We observed the majority of microglia in the DCL directly contacting Brn3+ RGCs. But due to the high density of RGCs, it was unclear whether this microglia-RGC contact was simply due to chance. Therefore, we analyzed the percentage of Nbl microglia contacting migrating RGCs, where it was easier to determine meaningful interactions (Fig. 1F; G; n = 4, 4, and 6 animals at e12.5, e14.5, and e16.5). Even though retinal progenitors vastly outnumber migrating RGCs in the Nbl, almost 50% of microglia in the Nbl contacting migrating Brn3+ RGCs at e14.5, which persisted at e16.5 (Fig. 1G).

Microglia are important for the elimination of apoptotic cells during development, and apoptosis facilitates microglia entry and positioning in the zebrafish CNS (Casano et al., 2016; Xu et al., 2016). Therefore, we also assessed the distribution and contact of microglia to cleaved caspase-3-positive (CC3+) cells. Consistent with previous reports, overall apoptosis levels were fairly low at the time points assessed. Of total microglia present in the retina, only ~15% contacted CC3+cells at e12.5 and 7% at e16.5 (Fig. 1H; n = 4 e12.5; n = 7 e16.5). Therefore, microglia mainly reside in the DCL and primarily associate with neurons during embryonic retinal neurogenesis.

Loss of colony stimulating factor 1 signaling conditionally and selectively depletes retinal microglia
To determine their impact on neurogenesis, we designed a genetic strategy to eliminate microglia. Colony stimulating factor 1 receptor (Csfr1) is essential for microglia survival in the brain (Erblich et al., 2011; Nandi et al., 2012) as well as the retina (Wang et al., 2016), and pharmacological inhibition of CSF1R signaling results in microglial death (Elmore et al., 2014). Because CSF1R is also expressed in neural progenitors (Nandi et al., 2012; Chitu et al., 2016),
Figure 1. Microglial density is dynamic in the developing retina, and microglia primarily associate with newborn neurons. A–C, Representative confocal images of retinal cross sections and central regions (A’–C’) at e12.5, e16.5, and P0: DAPI (blue), Iba1 (purple), Cx3cr1-gfp (green), and Brn3 (red). Dashed line indicates the boundary between the retina and vitreous where Iba1+ vitreal macrophages reside (yellow arrowheads). NbL and DCL outlined in B’. D, qRT-PCR of whole-retina samples over embryonic development. Levels of Cx3cr1 and Iba1 expression at various ages relative to P60 and normalized to β actin (n = 3 each). qPCR graph represents fold change relative to P60. Error bar indicates the SEM of Ct values.

E, Microglial density in DCL and NbL at e12.5, e14.5, and e16.5 (n = 4, 4, and 6 animals, respectively; two-way ANOVA: interaction, F(2,22) = 9.265, p = 0.0012; age, F(2,22) = 33.12, p < 0.0001; retinal layer, F(2,22) = 33.12, p < 0.0001; Sidak’s multiple-comparisons: DCL vs NbL at e12.5, t(22) = 8.842, p < 0.0001; at e14.5, t(22) = 3.206, p = 0.0122; e14.5 vs e16.5, t(22) = 7.24, p < 0.0001; Sidak’s multiple-comparisons comparing age: e12.5 vs e14.5, t(22) = 0.493, p = 0.948; e12.5 vs e16.5, t(22) = 7.24, p < 0.0001; e14.5 vs e16.5, t(22) = 0.493, p = 0.948). F, High-resolution confocal images with the Z plane of Iba1+ microglia in the NbL in contact with a migrating Brn3+ RGC (left) or not in contact (right). Iba1+ microglia (green) and Brn3+ RGCs (red). Z plane shown to the right and bottom of images. White cross represents point of interest.

G, Percentage of Iba1+ microglia in the NbL-contacting Brn3+ RGCs at e12.5, e14.5, and e16.5 (n = 4, 4, and 6 animals, respectively). H, Percentage total Iba1+ microglia contacting CC3+ cells at e12.5 and e16.5 (n = 4 retinas, e12.5; n = 7 retinas, e16.5). Scale bars: 100 μm for whole-retina cross sections, 50 μm for high-magnification central region, and 10 μm for microglia contact in NbL. Graphs represent the mean; error bars indicate SEM. Four or five sections per retina were analyzed. ****p < 0.0001. *p < 0.05.
we developed a targeted strategy crossing mice expressing a floxed Csfr1 allele (Li et al., 2006) to the inducible Cx3cr1creERT2 mouse line (Yona et al., 2013) to conditionally disrupt the Csfr1 gene in the myeloid lineage (Fig. 2A). Tamoxifen was administered to pregnant dams at e9.5, e11.5, and e13.5 by oral gavage (Fig. 2B). To first test the specificity and efficiency of the system, we used a Rosa-tdTomato reporter line to examine Cre activity both in the absence of tamoxifen and following our three-dose regimen (Cx3cr1creERT2 Rosa-tdTomato) (Fig. 2C,D). In the absence of tamoxifen, very few Iba1⁺ cells (1.58 ± 0.54%) showed...
Cre activity by tdTomato expression at e16.5, suggesting negligible background activity (Fig. 2C,D, top; n = 6). In contrast, at e14.5, immediately following three doses of tamoxifen, 100% of Iba1+ cells were tdTomato+ (Fig. 2C; n = 3; p < 0.0001), confirming the efficacy of Cx3cr1creERT2 in retinal microglia.

Following tamoxifen administration to pregnant dams (Fig. 2B), retinas from Cx3cr1creERT2; Csf1rfl/fl (Cre) e16.5 embryos displayed a substantial reduction in the number of Iba1+ cells compared with littermate controls exposed to tamoxifen and homozygous for the floxed allele but lacking Cre expression (no Cre;Csflrfl/fl) (Fig. 2D–F). Embryos heterozygous for the floxed Csf1r allele (Cx3cr1creERT2; Csf1rfl/+ ) had a slight reduction in microglial density and therefore were not used as controls (Fig. 2D, middle). In Cx3cr1creERT2; Csf1rfl/fl retinas, we found a 70% reduction in microglial density at e14.5 compared with no Cre; Csf1rfl/fl retinas (n = 5, no Cre; n = 8, Cre; Sidak’s multiple-comparisons, p = 0.0006; Cre, 25.98 ± 7.06 Iba1/mm²; no Cre, 88.63 ± 17.78 Iba1/mm²). At e16.5, microglial density was similarly reduced in Cx3cr1creERT2; Csf1rfl/fl retinas (25.25 ± 6.10 Iba1/mm²), despite the general increase in microglial density in the control, no Cre; Csf1rfl/fl (119.01 ± 4.88 Iba1/mm²) (Fig. 2F; n = 6, no Cre; n = 6, Cre; Sidak’s multiple-comparisons, p < 0.0001). Surviving microglia from Cx3cr1creERT2; Csf1rfl/fl retinas, in general, had increased soma size and reduced branching (Fig. 2E). To confirm that microglia were absent and not simply downregulating Iba1, we assessed the number of tdTomato+ cells in Cx3cr1creERT2; Rosa-tdTomato; Csf1rfl/fl retinas and found a similar reduction in density, to 25.83 ± 5.81 tdTomato/mm² [Figure 2G; n = 3 controls (Cx3cr1creERT2; Rosa-tdTomato; Csf1rfl/fl); n = 5 Cx3cr1creERT2; Rosa-tdTomato; Csf1rfl/fl, p < 0.0001]. Microglial density returned to WT levels ~e20.5/P0 (Fig. 2H; n = 3 each; p = 0.293), consistent with reports of microglia repopulation after depletion in the adult CNS (Elmore et al., 2014; Huang et al., 2018a,b).

There was significant tdTomato+ expression outside of the retina as C33CR1 is expressed in other myeloid cells in the eye, including in vitreal macrophages. However, Cx3cr1+ microglia within the retina were selectively vulnerable to Csf1r loss, congruous with published work (Elmore et al., 2014, 2015; Hilla et al., 2017). Vitreal macrophages were indeed increased in Cx3cr1creERT2; Csf1rfl/fl retinas compared with littermate controls (data not shown; n = 3 each; two-tailed Student’s t test, p = 0.0006). Therefore, retinas from Cx3cr1creERT2; Csf1rfl/fl animals (referred to as “depleted” hereafter) show a significant and profound loss of microglia following tamoxifen exposure, without depletion of surrounding macrophage populations during a specific time window and without disrupting Csf1r signaling in progenitors. This genetic strategy allows targeted assessment of microglia function during embryonic retinal neurogenesis.
Microglia regulate RGC density in the embryonic retina

Because microglia closely associate with newborn neurons, we asked whether microglia influence their numbers. We initially focused on RGCs because they are the first-born and most abundant neuron of the retina at early embryonic stages. Mouse RGC genesis initiates at e10.5 and concludes around birth, with peak production at e13.5-e14.5 (Sidman, 1961; Young, 1984). We performed immunostaining for Brn3 on cryosections of depleted and control embryos at e14.5 and e16.5 and analyzed the density of Brn3-positive RGCs in a fixed area of the retina, the dorsal central region. Compared with littermate controls, depleted retinas had increased RGC density during peak RGC generation at e14.5 (control, 6880 ± 94.03; depleted, 8045 ± 139.4 Brn3+/mm²) (Fig. 3A, B; n = 5 control; n = 8 depleted; p = 8.6E-05) as well as 48 h later, at e16.5 (control, 6666 ± 120.5; depleted, 7393 ± 203.6 Brn3+/mm²) (Fig. 3C, D; n = 3 each; p = 0.037). Therefore, these data suggest that microglia normally restrict RGC number during embryonic retinal development.

To confirm our findings that microglia were regulating RGC density, we used pharmacological inhibition of microglia to selectively perturb microglial function. Minocycline, a tetracycline derivative, is commonly used to suppress microglial activity during development (Schafer et al., 2012; Cunningham et al., 2013; Kobayashi et al., 2013; Ueno et al., 2013; Shigemoto-Mogami et al., 2014). Minocycline or vehicle alone was administered once a day to pregnant dams from e12.5 to e15.5 by oral gavage (Fig. 4A). First, we confirmed microglial inhibition by whole-retina qRT-PCR. Cx3cr1, which is not altered with microglial activation, was not signifi-

**Figure 4.** Pharmacological inhibition of microglia increases RGC density with no change in other early born cell types. A, Minocycline dosing regimen targeting embryonic retinal neurogenesis. The 120 mg/kg of minocycline or vehicle alone was given by oral gavage once daily for 4 d beginning at e12.5. B, Whole-retina qRT-PCR at e16.5 analyzing microglia transcripts Cx3cr1 and Iba1 (n = 3 control, n = 10 minocycline-treated; Cx3cr1 t(14) = 0.9771, p = 0.350; Iba1 t(14) = 4.127, p = 0.0017), normalized to β-actin and fold change relative to vehicle only controls. qPCR graph represents fold change. Error bars indicate the SEM of ΔCt values. C, Quantification of GFP+ cells in control and minocycline-treated retinal cross sections (n = 9 animals each; t(16) = 0.4183 p = 0.681 with Welch’s correction). D, Representative retinal cross sections at e16.5 of control and minocycline-treated retinas: DAPI (blue) and Cx3cr1-gfp (green). E, Higher-magnification images of dorsal central region. F, High-magnification view of individual GFP+ microglia from retinal whole mounts. G, Representative retinal cross sections of control and minocycline-treated animals at e16.5 with higher-magnification analyzed dorsal central region of RGCs. Higher-magnification view below (F’); Brn3+ RGCs (red) and GFP+ microglia (green). H, Quantification of dorsal central Brn3+ RGC density in control and minocycline-treated retinas at e16.5 (n = 6 animals each; t(10) = 2.53, p = 0.0299). Individual dots represent means for each retina. I, Representative images of dorsal central region analyzing horizontal and amacrine cells: Brn3a+ RGCs (red) and calbindin + (green). J, Quantification of calbindin+ Brn3a+ cells at e16.5 of control and minocycline-treated retinas (n = 6 control, n = 5 treated; t(10) = 0.318, p = 0.758). K, Representative images of dorsal central region Rxrγ+ cells along the apical surface. Rxrγ+ (teal). L, Quantification of Rxrγ+ Brn3+ cell density along 300 μm of the apical surface at e16.5 of control and minocycline-treated retinas (n = 4 control, n = 4 treated; t(7) = 1.394, p = 0.213). Scale bars: 100 μm for whole retina cross sections (D, F) and 50 μm for higher-magnification central regions in (D’, F’, H, J), 10 μm for individual microglia (E). Graphs represent mean ± SEM. ***p < 0.001. *p < 0.05.
cantly changed, whereas *Iba1* mRNA was reduced nearly 60% in minocycline-treated retinas compared with vehicle-only controls, suggesting efficient microglial inhibition (Bosco et al., 2008; Kobayashi et al., 2013). Analogous to depletion experiments, we observed a significant increase in RGC density in minocycline-treated retinas compared with controls (Fig. 4F, G; *n = 6* each; *p = 0.0299). To determine whether other early born cell types were affected, we assessed calbindin\(^+\) Brn3a\(^-\) amacrine and horizontal cells and found no significant difference with treatment (Fig. 4H, I; *n = 6* control; 5 minocycline; *p = 0.758). We also examined control and minocycline-treated retinas at P6 after amacrine cell genesis is complete and observed no consistent change in calbindin\(^+\) amacrine cell density (data not shown). Similarly, cone (Rx\(\gamma\) \^+\) Brn3\(^-\)) density was unchanged with minocycline treat-
controls. EdU was administered at e12.5, BrdU at e13.5, and an-
erated RGCs were persisting in depleted retinas relative to
formed a longer pulse to determine whether, instead, newly gen-

#### Figure 6. Inhibition of microglia does not change retinal cell apoptosis or alter microglial contact with apoptotic cells.

**A**. Representative retinal cross sections of control and minocycline-treated animals at e16.5 with higher magnification (C’): DAPI (blue) and CC3 + apoptotic cells (white). **B**. CC3 + cells at e16.5 of control and minocycline-treated retinas (n = 6 animals each; two-way ANOVA: interaction, F(1,20) = 0.039, p = 0.846; treatment, F(1,20) = 0.597, p = 0.449; retinal layer, F(1,20) = 0.9473, p = 0.342; Sidak’s multiple-comparisons: minocycline vs control DCL, t(20) = 0.685, p = 0.7511; NBL, t(20) = 0.407, p = 0.903). **C**. Number of CC3 + cells at e16.5 contacted by microglia (n = 7 each; t(12) = 0.3712, p = 0.717). **D**. Average distance of microglia to a CC3 + cell. Each dot represents the mean distance for a particular retina (n = 7 each; t(12) = 1.162, p = 0.268). **E**. CC3 + cells at e13.5 of control and minocycline-treated retinas (n = 3 animals each; t(4) = 0.498, p = 0.645). Scale bars: 100 μm for whole-retina cross sections (A) and 50 μm higher-magnification central regions (A’). Graphs indicate mean with SEM. Individual dots represent individual retinas.

### Perturbation of microglia does not change retinal progenitor proliferation, RGC genesis, or RGC apoptosis

To determine whether more RGCs were produced, we first as-
ssessed progenitor proliferation in minocycline-treated and con-
rol retinas. We reasoned that, if microglial perturbation was
might exit the cell cycle and, consequently, be diminished in
creasing differentiation of RGCs, normally mitotic progenitors
were suggested to be diminished in minocycline-treated retinas. However, we did not observe a
change in the number of CC3 + cells if microglia were simply clearing dying RGCs.

Because there was no change in activated CC3 expression in
minocycline-treated animals and no change in RGC genesis, we
hypothesized that microglia might eliminate non-CC3 + RGCs.

Consistent with this hypothesis, we observed many phagocytosis events at e12.5 and e13.5 in retinal whole mounts by confocal

**Figure 6.** Inhibition of microglia does not change retinal cell apoptosis or alter microglial contact with apoptotic cells. A, Representative retinal cross sections of control and minocycline-treated animals at e16.5 with higher magnification (C’: DAPI (blue) and CC3 + apoptotic cells (white). B, CC3 + cells at e16.5 of control and minocycline-treated retinas (n = 6 animals each; two-way ANOVA: interaction, F(1,20) = 0.039, p = 0.846; treatment, F(1,20) = 0.597, p = 0.449; retinal layer, F(1,20) = 0.9473, p = 0.342; Sidak’s multiple-comparisons: minocycline vs control DCL, t(20) = 0.685, p = 0.7511; NBL, t(20) = 0.407, p = 0.903). C, Number of CC3 + cells at e16.5 contacted by microglia (n = 7 each; t(12) = 0.3712, p = 0.717). D, Average distance of microglia to a CC3 + cell. Each dot represents the mean distance for a particular retina (n = 7 each; t(12) = 1.162, p = 0.268). E, CC3 + cells at e13.5 of control and minocycline-treated retinas (n = 3 animals each; t(4) = 0.498, p = 0.645). Scale bars: 100 μm for whole-retina cross sections (A) and 50 μm higher-magnification central regions (A’). Graphs indicate mean with SEM. Individual dots represent individual retinas.
Microglia are phagocytic at embryonic stages and interact with RGCs. A, High-resolution confocal image of microglial engulfment of an apoptotic cell (CC3⁺): DAPI (blue), Cx3cr1-gfp⁺ microglia (green), Brn3⁻ RGCs (red), and CC3⁻ (white). B, Microglia engulfing Brn3⁻ RGC. Right, bottom, Z-planes: Cx3cr1-gfp⁺ microglia (green) and Brn3⁻ RGCs (red). C, D, Microglia interacting with non-CC3⁺ RGCs: DAPI (blue), Cx3cr1-gfp⁺ microglia (green), Brn3⁻ RGCs (red), and CC3⁺ (white). E–J, IMARIS-based 3D reconstruction of microglia interacting with RGCs: Cx3cr1-gfp⁺ microglia (green), Brn3⁻ RGCs (red), and CC3⁺ (white). REconstruction of C. G, Reconstruction of D. J, Genes associated with phagocytosis assessed at e12.5 relative to P0 by whole-retina qRT-PCR. Normalized to β-actin (n = 3 each; Mertk, t₂₀ = 18.74, p < 0.0001; Cd68, t₂₀ = 6.71, p = 0.0026; C1qb, p < 0.0001; C3, t₂₀ = 7.33, p = 0.0018). qPCR graph represents fold change. Error bars indicate the SEM of 8 C₃ values. H, Percentage of Brn3⁺ RGC density in depleted retinas normalized to littermate control retinas at e20.5/P0 (n = 5 retinas/3 animals each; one-sample t test, t₂₀ = 6.895, p = 0.0023). Scale bars: E, F, 10 μm; G, 3 μm; H, I, 5 μm. Unpaired Student’s t test was used to determine significance of D, C values. ****p < 0.0001. **p < 0.01. Movie 4 is of C, F. Movie 3 is of D, G. Movie 1 is of H. Movie 2 is of J.

Figure 7. Microglia are phagocytic at embryonic stages and interact with RGCs. A, High-resolution confocal image of microglial engulfment of an apoptotic cell (CC3⁺): DAPI (blue), Cx3cr1-gfp⁺ microglia (green), Brn3⁻ RGCs (red), and CC3⁻ (white). B, Microglia engulfing Brn3⁻ RGC. Right, bottom, Z-planes: Cx3cr1-gfp⁺ microglia (green) and Brn3⁻ RGCs (red). C, D, Microglia interacting with non-CC3⁺ RGCs: DAPI (blue), Cx3cr1-gfp⁺ microglia (green), Brn3⁻ RGCs (red), and CC3⁺ (white). E–J, IMARIS-based 3D reconstruction of microglia interacting with RGCs: Cx3cr1-gfp⁺ microglia (green), Brn3⁻ RGCs (red), and CC3⁺ (white). REconstruction of C. G, Reconstruction of D. J, Genes associated with phagocytosis assessed at e12.5 relative to P0 by whole-retina qRT-PCR. Normalized to β-actin (n = 3 each; Mertk, t₂₀ = 18.74, p < 0.0001; Cd68, t₂₀ = 6.71, p = 0.0026; C1qb, p < 0.0001; C3, t₂₀ = 7.33, p = 0.0018). qPCR graph represents fold change. Error bars indicate the SEM of 8 C₃ values. H, Percentage of Brn3⁺ RGC density in depleted retinas normalized to littermate control retinas at e20.5/P0 (n = 5 retinas/3 animals each; one-sample t test, t₂₀ = 6.895, p = 0.0023). Scale bars: E, F, 10 μm; G, 3 μm; H, I, 5 μm. Unpaired Student’s t test was used to determine significance of D, C values. ****p < 0.0001. **p < 0.01. Movie 4 is of C, F. Movie 3 is of D, G. Movie 1 is of H. Movie 2 is of J.

microscopy and IMARIS-based 3D rendering (Fig. 7A–I). While CC3⁺ cells were rare, we did observe microglia engulfing CC3⁺ apoptotic cells that were almost always Brn3⁻ (Fig. 7A, E). More abundantly, however, we found microglia contacting and interacting with Brn3⁻ RGCs (Fig. 7B–D, F–I). Analysis through the Z plane verified microglia ensheathing RGCs and entire Brn3⁺ cells within microglia (Fig. 7B). Additionally, containing with CC3⁺ revealed that these RGCs were not undergoing CC3-mediated apoptosis (Fig. 7C, D, F, G; Movies 3, 4, 5). Microglia formed phagocytic cups (Fig. 7C, F; Movie 4) and also ensheathed entire Brn3⁻ RGCs (Fig. 7B, D, G–I; Movies 1, 2, 3). We also observed what appeared to be Brn3⁻ labeled fragments inside microglia (Movie 5). Many of these events were occurring right at the interface of the DCL and NBL, suggesting that newly born RGCs were being targeted, consistent with our BrDu analysis (Fig. 5F).

To further test whether microglia regulate RGC number by engulfment, we assessed microglia gene expression patterns by whole-retina qRT-PCR. We analyzed genes at e12.5 relative to P0, the end of embryonic development when microglia density is comparable and RGC generation is largely complete. We analyzed genes associated with phagocytosis: recognition receptor Tyrosine-protein kinase Mer (Mertk), lysosomal protein Cd68, complement component 1q (C1qb), and complement component 3 (C3). Relative to P0, all genes were highly upregulated at e12.5 (Fig. 7J; n = 3 each; Mertk, p = 4.8E-05; Cd68, p = 0.0031; C1qb, p = 0.0012; C3, p = 0.0018). We confirmed that these gene expression patterns were not due to contamination from peripheral macrophages because we could not amplify the macrophage-specific gene, Ccr2, by qPCR at any age (data not shown). We next asked whether the subset of RGCs being eliminated were viable. We depleted microglia as before (Fig. 2) and aged animals until e20.5/P0. If the normally eliminated RGCs were viable, we would predict a sustained increase in RGC density at birth. Consistent with this, Brn3⁺ RGC density was increased compared with littermate controls at e20.5/P0 by ~20% (Fig. 7K; n = 3 animals/5 retinas; one-sample two-tailed t test p = 0.0023). These data suggest that microglia are contacting and eliminating viable RGCs.
Complement proteins and phagocytosis are reduced following minocycline, and CR3/Cd11b KO retinas have increased RGC density

Minocycline has previously been implicated in reducing phagocytic activity (Schafer et al., 2012). Therefore, we proposed that readouts of phagocytosis would be diminished in minocycline-treated retinas. We first assessed the lysosomal-associated protein, Cd68, in retinal cross sections of animals given two doses of minocycline or vehicle only once a day at e12.5 and e13.5 and analyzed 2 h later (Fig. 8A). While there was no significant reduction in total density of GFP+ microglia in treated retinas, the density of microglia with visible lysosomal compartments (GFP+CD68+) was significantly reduced compared with controls (Fig. 8B; n = 3 each; p = 0.044). We then assessed gene expression of candidate phagocytosis genes in e13.5 minocycline and control retinas. We confirmed efficacy of minocycline treatment by a ~38% reduction in Iba1 mRNA (Fig. 8C; n = 8 controls; n = 12 minocycline-treated; p = 0.0046). However, common recognition receptors and associated phagocytosis genes were largely unchanged (Fig. 8C). Mertk, Milk fat globule
epidermal growth factor 8 (Mfge8), and Itgav of the vitronectin receptor (VNR), which recognize exposed phosphatidylserine, were not significantly altered following minocycline treatment (n = 8 controls; n = 12 minocycline-treated; MertK, p = 0.732; Mfge8, p = 0.516; VNR, p = 0.144). Tyrobp, which encodes DAP12, a coreceptor previously implicated in the recognition of dying cells (Wakselman et al., 2008), was not significantly down-regulated following minocycline treatment (p = 0.197). However, Lipoprotein receptor-related protein 1 (Lrp1), which can recognize C1q and exposed Calreticulin on stressed or dying cells, was significantly downregulated with treatment (p = 0.013) (Brown and Neher, 2014). Because complement proteins were highly upregulated at e12.5 (Fig. 7), we measured expression of Cd11b, a subunit of the CR3 as well as C3 and C1q. Minocycline treatment significantly reduced expression of both Itgam (Cd11b) and C3 but not C1qb at e13.5 (Fig. 8D, n = 8 controls; 12 minocycline; Itgam p = 0.008; C3, p = 0.011; C1qb, p = 0.314); however, at e16.5, we also saw a significant reduction in C1qb expression (Fig. 8D; n = 3 control; n = 10 minocycline; p = 0.00047). We also analyzed expression of Merk, VNR, Mfge8, Gas6, Calreticulin, and “don’t eat me” signal Cd47 at e16.5 and found that, again, none was altered (data not shown). Thus, of the known recognition receptors and accessory proteins known to be important for microglia phagocytosis, component complements were selectively downregulated with minocycline treatment.

To determine whether complement may be marking RGCs for phagocytic elimination, we assessed protein localization of C1q by immunostaining. We found that microglia highly express C1q as expected, but also observed Brn3+ RGCs were colabeled with C1q in whole-mount retinas at e13.5 (Brn3+ C1q+ GFP−) (Fig. 8E). Furthermore, we observed contact between GFP+ C1q+ microglia and C1q− Brn3+ RGCs (Fig. 8E1,F). We did find that C1q expression only localized to a subset of RGCs (Fig. 8E2,E3). This was confirmed in retinal cross sections at e16.5, which again showed that a subset of Brn3+ RGCs were C1q+ (Fig. 8F). We predominately saw C1q− Brn3+ RGCs along the edge of the DCL, consistent with our hypothesis that microglia target newly born RGCs. At P0, C1q was deposited in the emerging inner plexiform and nerve fiber layers, but we did not observe C1q− Brn3+ RGCs, suggesting that RGCs are marked during a narrow developmental window (data not shown). While both microglia and RGCs can produce C1q (Stevens et al., 2007; Fonseca et al., 2017), only microglia express complement receptor 3 (CR3, Cd11b) within the CNS (Jeong et al., 2013). Because Cd11b transcript was diminished (Itgam; Fig. 8D), we next tested whether Cd11b protein was also reduced following minocycline treatment. In retinal cross sections at e13.5, we observed a significant reduction in the density of Cd11b+ microglia in minocycline-treated retinas compared with controls similar to previous work (Schafer et al., 2012) (Fig. 8G,H; n = 3 each; p < 0.02).

We next directly tested whether complement signaling through CR3 was required for regulation of RGC number. Therefore, we analyzed RGC density in CR3 KO, with the prediction that RGCs would be increased in the absence of the recognition receptor. Compared with WT littermate controls (CR3 WT), we found P0 CR3 KOs had significantly more Brn3+ cells per millimeter (Fig. 8I,K; n = 5 animals/10 retinas WT and n = 5 animals/9 retinas KO; normalized to controls, one-sample two-tailed t test, p = 0.006) with no change in microglial density by Iba1 immunofluorescence (Fig. 8I,J; n = 5 animals/10 retinas WT and n = 5 animals/9 retinas KO; two sample two-tailed t test, p = 0.122). Together, these results suggest that microglia use complement signaling to recognize and eliminate a subset of non-C3+, newborn RGCs.

Discussion

The proper development of the CNS, including the retina, requires the appropriate balance of neuron production and elimination to attain the correct number of cell types (Oppenheim, 1991). It is estimated that half of the original cell population in the developing CNS is eventually eliminated (Oppenheim, 1981; Burek and Oppenheim, 1999). Therefore, signals facilitating the delicate balance between cell survival and cell death are indispensable for maintaining tissue homeostasis. The most studied cell elimination processes during development commonly involve apoptotic programs (Jacobson et al., 1997; Yamaguchi and Miura, 2015). Generally, initiation of a cascade of proapoptotic events occurs in one of two ways: self-execution driven by intrinsic or extrinsic signals, such as death ligands (Johnson and Deckwerth, 1993). However, there is increasing evidence that there are non–cell-autonomous ways to regulate neuron number that do not require apoptosis.

During retinal development, ~50% of RGCs produced will undergo developmental death during the first postnatal week (Farah, 2006). Postnatal RGC loss requires apoptosis and is hypothesized to be a result of overproduction of RGCs competing for limited neurotrophic supply and by activity-dependent processes (Perry et al., 1983; Oppenheim, 1991; Péquignot et al., 2003; Farah, 2006). However, most investigations of RGC developmental death neglect prenatal periods, likely because little apoptosis, identified by CC3 and TUNEL, is detected in the DCL prenatally (Young, 1984) and ongoing RGC genesis makes analysis complex. Direct counts of RGC axons in other mammals reveals an embryonic wave of RGC loss (Crespo et al., 1985; Williams et al., 1986), and analysis of RGC somas at individual time points in mouse (Farah and Easter, 2005) predicts a 10%–15% loss of RGCs before birth. Here, we find that this embryonic wave
Figure 8. Complement proteins are downregulated with minocycline treatment, and loss of CR3/Cd11b results in increased RGC density. A, Minocycline dosing regimen at e12.5 and e13.5 and death 2 h later. B, Quantification of overall microglial density (GFP+/mm²) and the density of microglia with Cd68+ lysosomal compartments (Cd68+/GFP+/mm²) in minocycline-treated and control retinas at e13.5 (n = 3 each; control, 159.2 ± 7.81; minocycline, 132.9 ± 6.66; GFP+/mm²; t(4) = 2.913, p = 0.044). C, Whole-retina qRT-PCR of Iba1 and microglial receptors commonly associated with phagocytosis (n = 6 control, n = 3 micocycline; Iba1, t(10) = 3.23, p = 0.0046; Merk, t(10) = 0.348, p = 0.732; VNR, t(10) = 1.53, p = 0.144; Mfge8, t(10) = 0.673, p = 0.516; Tyrobp, t(10) = 1.34, p = 0.197; LRP, t(10) = 2.77, p = 0.013). Normalized to β-actin and relative to age-matched vehicle only controls. D, Whole-retina qRT-PCR of complement proteins (n = 6 controls, n = 11 minocycline-treated; Cd11b, t(18) = 2.96, p = 0.008; C3, t(16) = 1.912, p = 0.074; e13.5, C1qb, t(10) = 1.04, p = 0.314; e16.5, C1qb, n = 3 controls, 10 treated; t(18) = 4.91, p = 0.0005). Normalized to β-actin and relative to age-matched vehicle only controls. E, e13.5 retinal whole mounts of Cx3cr1-gfp (green), Brn3 (red), C1q (white), and merge. Insets, C1q+RGC contacted by microglia (1), C1q+RGC (2), and C1q+RGC (3). Yellow arrowheads indicate C1q+RGCs. F, e16.5 retinal cross sections of Cx3cr1-gfp (green), Brn3 (red), C1q (white), and merge. Inset, Magnification of C1q+RGCs along DCL border. Yellow arrowheads indicate C1q+RGCs. G, e13.5 retinal cross sections of Cd11b immunostaining: DAPI (blue), Cx3cr1-gfp (green), and Cd11b+ (red). Yellow arrowheads indicate Cd11b+ microglia. H, Quantification of microglia highly expressing Cd11b (GFP+/Cd11b+) at e13.5 (n = 3 each; control, 86.7 ± 3.71; minocycline, 55.4 ± 7.48; t(4) = 3.75, p = 0.02). I, Retinal cross sections of e16.5 control (CR3 WT) and CR3 KO animals: Iba1 (green) and Brn3 (red). J, Analysis of microglial density (Iba1/mm²) in CR3 KO and littermate WT controls (n = 5 animals/10 retinas WT, 127.4 ± 5.42; n = 5 animals/9 retinas KO, 140.3 ± 5.74; two-sample t test, t(10) = 1.626, p = 0.122). K, Analysis of RGC density in CR3 KO and controls. Data were normalized to littermate controls because 3 litters were used (n = 5 animals/10 retinas WT, n = 5 animals/9 retinas KO; one-sample t test, t(9) = 3.71, p = 0.006). Scale bars: 50 μm for retinal whole mounts and central regions of retinal cross sections, 10 μm for higher-magnification insets, and in G, C, D, qPCR graphs represent fold change. Error bar indicates the SEM of ΔCt values. Graphs represent mean ± h SEM. ***p < 0.001. **p < 0.01. *p < 0.05.
of RGC loss requires microglial presence and function with no change in caspase-dependent apoptosis programs.

Microglia can eliminate neurons in a matter of hours (Neher et al., 2011; Zhao et al., 2015), making phagocytic events hard to detect at static time points ex vivo. Nevertheless, increasing evidence suggests that phagocytosis is a highly regulated, complex process with functions beyond passive clearance of dying cells or cellular debris. The active elimination of stressed, but viable, cells has been dubbed phagoptosis, or primary phagocytosis, and events are well documented in culture (Brown and Neher, 2012, 2014; Vilalta and Brown, 2018). There is also evidence in vivo both during development and disease that microglia can eliminate nonapoptotic cells. During cortical development, microglia engulf viable neural progenitors to limit the number of neurons generated (Cunningham et al., 2013). Microglia contribute to retinal degeneration by the phagocytosis of living but stressed photoreceptors in Rd10 mutants (Zhao et al., 2015). Additionally, microglia phagocytose viable neurons during transient cerebral ischemia (Neher et al., 2013; Alawieh et al., 2018) and adult newborn dentate granule cells in a mouse model of temporal lobe epilepsy (Luo et al., 2016). We provide evidence that microglia also actively select a subpopulation of seemingly viable RGCs to be eliminated in the developing retina. It remains possible that microglia secrete factors to stimulate non–CC3-dependent death. However, we find microglial phagocytosis is high during relevant time periods, is regulated with minocycline treatment, and microglia frequently interact with and ensheath nonapoptotic RGCs. Because RGC density in microglia depleted retinas remains increased at birth, this suggests that these RGCs are viable and normally eliminated by phagocytosis.

To date, the molecular mechanisms driving phagoptosis in vivo are largely unknown. However, there is evidence that MerTK and Mge8 (Neher et al., 2013) are involved in engulfment of stressed neurons following ischemia. In a model of ischemic stroke, targeted inhibition of complement or KO of C3 limits microglial contact and engulfment of stressed, noncleaved caspase 3+ neurons (Alawieh et al., 2018). Here, we find that complement proteins are an important signal for RGC removal by microglia. The complement system has been implicated in development and disease with a primary focus on the ability of complement to tag synapses for pruning (Stevens et al., 2007; Schafer et al., 2012; Stephan et al., 2012; Zabel and Kirsch, 2013; Hong et al., 2016; Coulthard et al., 2018; Hawksworth et al., 2018). Complement is important for RGC-microglia interactions during postnatal periods by marking RGC synapses in the LGN for microglial engulfment (Schafer et al., 2012). We show that complement signaling via CR3 is required for normal elimination of RGCs embryonically because an excess of RGCs were present at P0 in the CR3 KO retina. It is likely other phagocytosis pathways also contribute because we see less of an increase in RGC density in CR3 KO retinas than is observed following microglial deplet.

The findings are consistent with previous work, where loss of complement receptor signaling did not completely abolish phagocytosis but reduced engulfment by ~50% (Schafer et al., 2012). One interesting candidate that may participate in RGC elimination is LRP because we observed a significant downregulation of its expression with minocycline treatment and LRP can recognize C1q to stimulate phagocytosis (Brown and Neher, 2014). These findings represent some of the first evidence that complement signaling can stimulate engulfment of entire neurons in vivo. This has major ramifications not only during development but also in pathological states.

Complement is upregulated early and implicated in driving pathology in various contexts of injury and neurodegeneration (Bonifati and Kishore, 2007; Zabel and Kirsch, 2013), including glaucoma, which is the progressive decline and loss of RGCs (Soto and Howell, 2014; Williams et al., 2017). During glaucoma progression, complement proteins, such as C1q, become localized to RGC synapses and cell bodies (Stevens et al., 2007). Therefore, it is an intriguing possibility that the developmental microglia-RGC interactions found here may reemerge in glaucoma.

We found that microglia were regulating RGC number embryonically, with no apparent effect on cones or amacrine cells, although effects on other cell types cannot be ruled out. Why a subset of seemingly viable RGCs would be eliminated during peak RGC genesis is unknown. Because RGC density is tightly regulated (Wang et al., 2005) and various “don’t eat me” signals limit aberrant phagocytosis (Elward and Gasque, 2003), it is unlikely that microglia target RGCs stochastically. An alternative hypothesis is that microglia target specific RGCs that may be less fit for their environment. Many factors can influence whether a newborn neuron will live or die during development, including sufficient neurotrophic support, proper migration, correct timing, cell–cell interactions, successful axon guidance and innervation, and sufficient neuronal activity (Yamaguchi and Miura, 2015). Cell competition can also drive elimination of viable, but less fit, cells during development (Gogna et al., 2015). A few reports have illustrated the ability of microglia to “sense” and eliminate neurons displaying cellular dysfunction and stress (Brown and Neher, 2012, 2014; Zhao et al., 2015). Therefore, it is possible that microglia eliminate stressed RGCs before they become a liability or less fit RGCs competing for limited space and resources. Our RGC labeling analysis with BrdU suggests that RGCs are primarily being targeted at least 24 h after birth. While this provides clues as to what could be driving their elimination, various possibilities remain. RGC axons reach the optic nerve 24–48 h after birth (Farah and Easter, 2005), suggesting that axon guidance mishaps could drive RGC elimination. Because both minocycline treatment and genetic depletion of microglia are systemic, it is possible that microglia may have important roles at other RGC compartments, including RGC targets in the brain, such as the superior colliculus or lateral geniculate nucleus. Interestingly, complement components are important for the proper migration of both neural crest cells and cortical neurons (Coulthard et al., 2018). Therefore, it is also plausible that targeted RGCs have improperly migrated. Because we identify C1q-positive RGCs along the edge of the DCL where migrating RGCs arrive, and we observe many microglia–RGC contact events, it is intriguing to speculate that there is a checkpoint for newborn RGCs. If true, this process may be another level of refinement important for CNS development and function.

Currently, it is unclear whether the addition of these normally eliminated RGCs has any long-term effects. By P6, we find a slight, but insignificant, increase in Brn3 density in minocycline-treated retinas (data not shown), suggesting that Brn3 density normalizes and excess neurons may be eliminated during postnatal apoptosis-mediated refinement (Farah, 2006).

While proper CNS development necessitates appropriate production of cell types, the successful elimination of a fixed proportion is essential for homeostasis and CNS refinement (Oppenheim, 1991). Here, we provide evidence for a novel mechanism of neuron elimination in the developing retina, whereby microglia directly limit seemingly viable RGCs by phagocytosis. We find this is partially dependent on complement signaling, which exposes an ancillary role for this ancient signaling system.
In addition, we uncover an avenue of microglia-neuron crosstalk that could have major implications during CNS development but also in complex contexts of injury and disease.

References


